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Venous thromboembolism (VTE) is a potentially fatal complication of superficial 
endovenous treatment. Proper risk assessment and thromboprophylaxis could mitigate 
this hazard, however there are currently no evidence-based or consensus guidelines. 
This study surveyed UK and Republic of Ireland vascular consultants to determine 
areas of consensus.  
 
Methods 
A 32-item survey was sent to vascular consultants via the Vascular and Endovascular 
Research Network (VERN) (phase-1). These results generated 10 consensus 
statements which were redistributed (phase-2). ‘Good’ and ‘very good’ consensus 




Forty-two consultants completed phase-1. This generated 7 statements regarding risk 
factors mandating peri-procedural pharmacoprophylaxis and 3 statements regarding 
specific pharmacoprophylaxis regimes. Forty-seven consultants completed phase-2. 
Regarding VTE risk factors mandating pharmacoprophylaxis, ‘good’ and 'very good' 
consensus was achieved for 5/7 and 2/7 statements respectively. Regarding specific 
regimens, ‘very good’ consensus was achieved for 3/3 statements. 
 
Conclusions 
The main findings from this study were that there was ‘good’ or 'very good' consensus 
that patients with any of the 7 surveyed risk factors should be given 
pharmacoprophylaxis with low-molecular-weight-heparin. High-risk patients should 





Endovenous thermal ablative procedures are first line for the management of 
superficial venous incompetence (SVI) of the lower limb. Supported by The National 
Institute for Health and Care Excellence Guideline (NICE CG167) recommendations 
(1), endothermal techniques have become the most common method for treating 
truncal SVI (2). There is general consensus that endovenous procedures confer a 
significant peri-procedural benefit when compared with open surgical treatment in 
terms of reduced morbidity and enhanced recovery (3–5). 
 
Like all varicose vein treatments, endovenous interventions for SVI are not without 
complications, one of the most important being the development of venous 
thromboembolism (VTE). VTE after superficial endovenous treatment most 
commonly occurs as a deep venous thrombosis (DVT) however, rarely VTE can 
manifest as a pulmonary embolism (PE), which may prove fatal. Such cases have 
attracted media coverage (6) and may have significant medico-legal implications for 
clinicians (7). Rates of DVT following endothermal ablation have been reported to be 
as high as 16% (8), however the 2 largest studies in this area suggest the true 
incidence lies between 0.5% and 3.2% (9,10). VTE risk assessment and targeted 
administration of pharmacoprophylaxis could mitigate this complication when 
patients have additional risk factors for VTE. At present there is an absence of 
evidence-based or consensus guidelines to inform clinicians in this area. The purpose 
of this study was to survey United Kingdom (UK) and Republic of Ireland (ROI) 
vascular surgeons about their practices regarding VTE risk stratification and 
subsequent pharmacoprophylaxis preferences during SVI interventions, with the aim 




A 2-phase survey was performed of UK and ROI consultant vascular surgeons 
between February 2017 and May 2019 via the Vascular and Endovascular Research 
Network (VERN), which is a vascular research collaborative consisting of vascular 
surgery trainees, vascular nurse specialists, vascular scientists and some vascular 
surgery consultants (11) with a proven track record for delivering multicentre research 
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(12–15). A modified Delphi consensus methodology was utilised (16). Surveys were 
created using the Google™ Forms platform and links to surveys were circulated to 
VERN members by email. Three follow-up emails per survey were sent as reminders. 
VERN members were asked to survey consultant vascular surgeons working in their 
own units, however consultants who were also VERN members were eligible to 
answer regarding their own practices. If multiple VERN members had surveyed the 
same consultant, only the first submitted response was used for that round of the 
survey. In situations where the surveyed consultant wished to remain anonymous, 
only the unit name was recorded. Responses relating to consultants from outside the 
UK and ROI were excluded from analysis. Collaborative authorship was offered to 
individuals completing the survey in accordance with ICMJE authorship guidelines 
(17). 
 
The 1st phase consisted of a 32-item survey (see supplementary material) asking 
consultants about the relative significance (Likert scale) of various possible VTE risk 
factors when considering a patient for endovenous treatment, and which risk factors 
would prompt them to prescribe VTE pharmacoprophylaxis (‘yes/no’ response). Risk 
factors chosen for inclusion in the 1st phase represented some risk factors from 
established VTE risk assessment tools such as the Caprini risk assessment model (18), 
but were largely based on risk factors felt to be most important, by the authors of the 
study, to patients undergoing superficial endovenous treatment. A 10-point Likert 
scale was used to grade the significance of each risk factor. There were further 
questions in phase 1 relating to which specific thromboprophylaxis regimes were 
preferred when indicated (multiple choice responses). 
 
The responses from the 1st phase questions were displayed graphically using 
histogram analysis and any questions with a significant skewness in the responses 
were taken forward to phase 2 to create consensus statements. 
 
The 2nd phase consisted of 10 statements (see Figure 3) where each statement could 
only be answered by a ‘yes’ or ‘no’ response. The responses to these 10 statements 
were then analysed to find areas of consensus. ‘Good’ and ‘very good’ consensus 
were defined a priori as acceptance or rejection by >67% and >85% of the 
respondents, respectively. A >67% acceptance or rejection rate was chosen to 
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represent a ‘good’ consensus based on a previous similar survey relating to deep 
venous interventions (19). A further classification of ‘very good’ consensus (>85%) 
was defined in this study to identify areas of particularly high agreement amongst 
consultants. 
 






The 1st phase received a total of 45 consultant responses. After removal of duplicate 
(n=3) responses (where multiple VERN members had surveyed the same consultant 
or where the consultant had additionally responded to the survey themself) there were 
42 unique and valid consultant responses available for analysis. For phase 1, each 
VERN member surveyed a median of 1 consultant (range 1 to 5 consultants). 
 
Consultants perceived a personal history of VTE, an inherited thrombophilia and 
reduced mobility / impaired calf muscle pump function as the 3 most significant risk 
factors for VTE when performing superficial endovenous treatment (Table 1). 
 
Similarly, the three most common risk factors prompting consultants to prescribe 
pharmacoprophylaxis during superficial endovenous treatment were a personal 
history of VTE, an inherited thrombophilia and reduced mobility / impaired calf 
muscle pump function (Table 2). 
 
The preferred thromboprophylaxis regimens amongst consultants were a single peri-
operative dose of low molecular weight heparin (LMWH) when treating patients 
deemed to be at ‘moderate’ risk for VTE development (Figure 1), and 5 to 7 days of 






Following histogram analysis of the responses from the first phase of the survey, ten 
‘yes/no’ statements were created with the aim of establishing consensus on when and 
how best to administer pharmacoprophylaxis for patients undergoing superficial 
endovenous treatment. Seven of these statements related to specific risk factors for 
VTE and 3 of these statements related to specific pharmacoprophylaxis regimens 
(Figure 3). 
 
The 2nd phase received a total of 58 responses. After removal of duplicate responses 
(n=8) and responses from non-UK or Ireland consultants (n=3), there were 47 unique 
and valid consultant responses available for analysis. For phase 2, each VERN 
member surveyed a median of 1 consultant (range 1 to 5 consultants). 
 
The consultant responses to each of the 10 consensus statements are shown in Figure 
4. ‘Good’ consensus (>67% consensus amongst consultants) was achieved for 5 
statements relating to VTE risk factors. ‘Very good’ consensus (>85% consensus 
amongst consultants) was achieved for the remaining 2 out 7 statements (statements 5 
and 7) relating to VTE risk factors and for all 3 statements relating to 




VTE following superficial endovenous treatment is relatively rare and these therapies, 
usually performed as a day case procedure, are considered to be low risk. As a result, 
clinicians may face significant scrutiny in the unfortunate circumstance that a VTE 
event does occur, particularly if VTE risk assessment was not performed, if the 
patient had not been adequately counseled and consented in relation to VTE, if 
appropriate thromboprophylaxis was not given and/or if the VTE was associated with 
significant morbidity or mortality. Most patients in the UK and ROI routinely receive 
compression garments following SVI intervention (20), with variable duration (21), as 
part of a treatment package to enhance treatment success and patient reported 
outcome measures (22). Pharmacological VTE prophylaxis here would be additional 




The decision about whether patients undergoing superficial endovenous treatment 
should receive pharmacoprophylaxis against VTE is frequently based on individual 
clinician opinion due to an absence of evidence-based or consensus guidelines (7,23). 
The aim of this study was to investigate these opinions by surveying UK and ROI 
consultant vascular surgeons and to determine areas of consensus practice. The main 
findings from this study were that there was ‘good’ or ‘very good’ consensus that 
patients with any of the 7 risk factors surveyed (BMI >30 kg/m2, impaired mobility / 
reduced calf muscle pump function, on HRT / hormonal contraception, a personal / 
family history of VTE or an inherited thrombophilia) should be given 
pharmacoprophylaxis. For 2 of the risk factors (a personal history of VTE or an 
inherited thrombophilia) there was nearly universal agreement that these patients 
should receive pharmacoprophylaxis when undergoing superficial endovenous 
treatment. When asked about how pharmacoprophylaxis should be delivered, there 
was ‘very good’ consensus amongst consultants that LMWH should be used. In 
addition, most consultants (>85%) felt that a single-dose of LMWH was sufficient for 
patients deemed to be at moderate risk of VTE, however patients deemed to be at 
‘high-risk’ should receive a longer course (between 1 - 2 weeks of LMWH). 
 
The issue of how to stratify patients undergoing superficial endovenous treatment 
who might be at increased risk for VTE has long been a problem. Traditional risk 
assessment tools such as those developed by Caprini (18) or the UK Department of 
Health (24) are potentially less appropriate for patients undergoing ambulatory 
endovenous procedures since most of the risk factors in these models are only 
applicable to patients undergoing major surgical intervention. Further research is 
needed to develop specific risk prediction tools for patients undergoing ambulatory 
endovenous procedures, however such studies will require large numbers of patients 
given the relatively low absolute incidence of VTE in this patient cohort. The 
responses from this study (both phases taken together) indicate agreement, at least 
amongst the UK and ROI surgeons studied, that a personal history of VTE, an 
inherited thrombophilia (and probably also reduced mobility / impaired calf muscle 
pump function) are regarded as the risk factors putting patients at the highest risk. 
Whether such factors could or should be used to stratify the duration of 
pharmacoprophylaxis treatment in this patient population clearly requires further 
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investigation since the current study only tested strength of agreement amongst 
surveyed consultants.  
 
The consensus regarding VTE pharmacoprophylaxis shown in this study provides 
clinicians with a steer as to what a body of UK and ROI consultant colleagues 
consider to be reasonable practice. However this study was not a trial of different 
methods of assessment nor did it study the effectiveness of one regime of 
pharmacological thromboprophylaxis over another.  
 
It is expected that clinicians inform patients of any serious risks related to a 
procedure, of guidelines on treatment choices and if a recommended treatment differs 
from what is specified in guidelines then clinicians must explain their rationale for not 
following the guideline (25). Practicing in accordance with consensus opinion used to 
afford clinicians a certain level of medico-legal protection should complications occur 
(26). However, since the landmark UK Supreme Court ruling in the case of 
Montogomery versus Lanarkshire Health Board the medico-legal position has shifted 
(27). It is no longer acceptable for clinicians to unilaterally decide what risks would 
be relevant to an individual patient. Instead it is now the duty of clinicians to inform 
patients undergoing a treatment of all relevant material risks attached to that treatment 
(25,27). 
 
There are a number of limitations to this study. Firstly, by surveying only the 
consultant grade there was a reasonable assumption that all respondents were 
competent and experienced at performing superficial endovenous treatments. 
However it is unreasonable to assume that these same clinicians also represent experts 
in the time-course, pathophysiology and effective management of VTE. This 
limitation may account for the finding in phase 1 that the preferred 
pharmacoprophylaxis regime amongst responding consultants was a single peri-
operative dose of LMWH when treating patients deemed to be at ‘moderate’ risk for 
VTE. The median time-course for VTE presentation is 11 days post-operatively (9), 
with the majority occurring within 30 days post-operatively (28). A single peri-
operative LMWH dose therefore represents ineffective prophylaxis and cannot be 
justified. The practice probably reflects learned historic vascular practice that was 
originally promoted as a medico-legal defensive aid rather than providing any benefit 
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for the patient in terms of VTE prophylaxis. Secondly, we only surveyed consultant 
vascular surgeons and did not survey the few consultants from other specialties who 
also perform these procedures such as consultant interventional radiologists. Thirdly, 
it is important to state that strength of agreement reported in this study does not relate 
to degree of VTE risk and, furthermore, this survey asked respondents regarding the 
relevance of individual risk factors and not risk factors in combination. Fourthly, this 
study only examined the risk factors felt to be most relevant (by the authors) to 
patients undergoing superficial endovenous surgery. Various other risk factors for 
VTE exist, such as a history of inflammatory bowel disease, congestive cardiac 
failure, chronic obstructive pulmonary disease or recent stroke, which were not 
examined in this study but may be important in a small minority of patients 
undergoing these procedures. Clinicians performing these procedures should be 
vigilant about taking a thorough medical history during the initial consultation aiming 
to elicit any and all such risk factors for VTE so as to best gauge the individual 
patient's VTE risk. Finally, we used members of the VERN research collaborative to 
approach consultants working in their units. Since most VERN members were trainee 
vascular surgeons, it was not possible to ensure the same consultants were surveyed 
during each phase of the study since trainees tended to move from one unit to another 
as they progressed through their training. In addition consultants performing 
superficial venous treatments exclusively in non-teaching hospitals or the private 
sector (where VERN members are unlikely to be based) were unlikely to be 
represented in this study.    
 
Despite these limitations, endovenous treatments for SVI are increasing (29,30) and 
therefore the results from this study, which surveyed consultants from across the UK 
and ROI (see acknowledgements for geographical locations), remain important since 
they inform on the current state of pharmacological thromboprophylaxis practices for 
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Tables & Figures 
 
Table 1. Consultant perceptions on the relative significance of various risk factors for 
VTE during superficial endovenous surgery. Data shown as median value and 
interquartile range (IQR), where 1 represents ‘very low risk’ and 10 represents ‘very 
high risk’. BMI, body mass index; HRT, hormone replacement therapy; VTE, venous 
thromboembolism. 
 
Risk factor Median (IQR) perceived significance value 
Age >75 years 6 (3.25 - 7) 
Age 61 - 74 years 5 (3 - 6) 
BMI >30 kg/m2  7 (5 - 8) 
Procedure duration >1hour 6 (5 - 7) 
Reduced mobility / impaired 
calf muscle pump function 
8 (6 - 9) 
Current smoking 6 (4 - 7) 
Use of HRT 7 (5.25 - 8) 
Use of hormonal 
contraception 
7 (6 - 8) 
Personal history of VTE 9 (8 - 10) 
Family history of VTE 7 (6 - 8) 
Long haul flight (>3 hours) 
within 4 weeks of procedure 
6 (3.25 - 7) 
Past history of malignancy 7 (6 - 8) 
Inherited thrombophilia 9 (7.25 - 10) 
Moderate / Major surgery 
within last 12 weeks 




Table 2. Consultant opinions on which risk factors for VTE would prompt 
pharmacoprophylaxis prescribing during superficial endovenous surgery. BMI, body 
mass index; HRT, hormone replacement therapy, VTE, venous thromboembolism. 
 
Risk factor 
Number (%) of consultants stating risk factor 
would prompt VTE pharmacoprophylaxis 
prescribing 
Age >75 years 21 (50.0) 
Age 61 - 74 years 19 (45.2) 
BMI >30 kg/m2  27 (64.3) 
Procedure duration >1hour 24 (57.1) 
Reduced mobility / impaired 
calf muscle pump function 
35 (83.3) 
Current smoking 17 (40.5) 
Use of HRT 31 (73.8) 
Use of hormonal 
contraception 
33 (78.6) 
Personal history of VTE 42 (100) 
Family history of VTE 28 (66.7) 
Long haul flight (>3 hours) 
within 4 weeks of procedure 
26 (61.9) 
Past history of malignancy 26 (61.9) 
Inherited thrombophilia 37 (88.1) 
Moderate / Major surgery 





Figure 1. Preferred thromboprophylaxis regimens amongst consultants when 
performing superficial endovenous surgery on a patient deemed to be at ‘moderate’ 






Figure 2. Preferred thromboprophylaxis regimens amongst consultants when 
performing superficial endovenous surgery on a patient deemed to be at ‘high’ risk of 






Figure 3. Ten consensus statements used for phase 2. LMWH, low molecular weight 






Figure 4. Consultant ‘yes/no’ responses to 10 consensus statements defined in 
Figure 3. 
 
 
